One of the possibilities to prevent rejection is by creating embryonic stem cell clones that are genetically identical to the patient. This can be achieved by fusing an egg (oocyte), the nucleus (containing the genetic material: DNA) of which is removed, with a patient's cell. The fused cell produced (containing only the DNA of the patient) is allowed to grow to the size of a few tens of cells, and stem cells are then extracted. Because they are genetically compatible with the patient, the patient's immune system will not reject differentiated cells derived from these embryonic stem cells. More commonly, they are obtained for research purposes from uncloned blastocysts, such as those discarded from in vitro fertilization clinics. Such cells might be rejected if transplanted into a patient, as they do not contain identical genetic information. A possible solution for this is to derive as many well-characterized embryonic stem cell lines from different genetic and ethnic backgrounds and use the cell line that is most similar to the patient; treatment can then be tailored to the patient, minimizing the risk of rejection.
The online edition of Nature Medicine published a study on January 23, 2005 which stated that the human embryonic stem cells available for federally funded research are contaminated with nonhuman molecules from the culture medium used to grow the cells, for example, mouse cells and other animal cells. The nonhuman cell-surface sialic acid can compromise the potential uses of the embryonic stem cells in humans, according to scientists at the University of California, San Diego*.
A study was published in the online edition of Lancet Medical Journal on March 8, 2005 that detailed information about a new stem-cell line which was derived from human embryos under completely cell- and serum-free conditions. This event is significant because exposure of existing human embryonic stem-cell lines to live animal cells and serum risks contamination with pathogens that could lead to human health risks. After more than 6 months of undifferentiated proliferation, these cells retained the potential to form derivatives of all three embryonic germ layers both in vitro and in teratomas. These properties were also successfully maintained (for more than 30 passages) with the established stem-cell lines. (Lancet Medical Journal)
Recently, in California, researchers have injected embryonic stem cells into mice as they developed in the womb. Upon maturing, it was found that some of the human ESCs had survived and two months after injection, the researchers found that the ESCs had undertaken "the characteristics of mouse cells" *.
Scientists in Australia have grown human prostate in mice using embryonic stem cells. In a world first, the scientists combined human embryonic stem cells with mouse prostate cells, and used a mouse as the host to grow the human prostate. The researchers were able to show that it was also functioning as a human prostate. Doctors world wide would now be able to use this prostate as a model for studying prostate cancer and disease, and to produce future drugs. (StemBlog.com - cloning and stem cell blog)
This article is licensed under the GNU Free Documentation License.
It uses material from the
"Embryonic stem cell".
Home Page • arts • business • computers • games • health • hospitals • home • kids & teens • news • physicians • recreation• reference • regional • science • shopping • society • sports • world